Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 6, 2026, 3:22 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524394 | NSE: VIMTALABS

Vimta Labs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 6, 2026, 3:22 am

Market Cap 1,959 Cr.
Current Price 439
Intrinsic Value₹421.40
High / Low 903/372
Stock P/E25.8
Book Value 93.3
Dividend Yield0.23 %
ROCE25.2 %
ROE19.4 %
Face Value 2.00
PEG Ratio2.06

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vimta Labs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Vimta Labs Ltd 1,959 Cr. 439 903/37225.8 93.30.23 %25.2 %19.4 % 2.00
Choksi Laboratories Ltd 62.4 Cr. 89.6 237/81.839.3 35.20.00 %9.20 %6.63 % 10.0
Industry Average1,959.00 Cr264.3032.5564.250.12%17.20%13.02%6.00

All Competitor Stocks of Vimta Labs Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 768182647373758590949810299
Expenses 55575848504749555761646864
Operating Profit 21242417232626303333343434
OPM % 27%29%29%26%31%36%35%35%37%35%35%34%35%
Other Income 1110-1-1-1-152230
Interest 1001110010000
Depreciation 88898888109101011
Profit before tax 1416168131617202825252623
Tax % 27%23%25%25%25%24%26%24%23%27%25%24%25%
Net Profit 101212691212152218192018
EPS in Rs 2.252.772.631.342.142.792.773.444.844.124.244.473.94

Last Updated: February 3, 2026, 3:46 pm

Below is a detailed analysis of the quarterly data for Vimta Labs Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 99.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Sep 2025) to 99.00 Cr., marking a decrease of 3.00 Cr..
  • For Expenses, as of Dec 2025, the value is 64.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 68.00 Cr. (Sep 2025) to 64.00 Cr., marking a decrease of 4.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 34.00 Cr..
  • For OPM %, as of Dec 2025, the value is 35.00%. The value appears strong and on an upward trend. It has increased from 34.00% (Sep 2025) to 35.00%, marking an increase of 1.00%.
  • For Other Income, as of Dec 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Sep 2025) to 0.00 Cr., marking a decrease of 3.00 Cr..
  • For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Sep 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Sep 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
  • For Tax %, as of Dec 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Sep 2025) to 25.00%, marking an increase of 1.00%.
  • For Net Profit, as of Dec 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Sep 2025) to 18.00 Cr., marking a decrease of 2.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 3.94. The value appears to be declining and may need further review. It has decreased from 4.47 (Sep 2025) to 3.94, marking a decrease of 0.53.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 9:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 127116138154183213181209276315289344392
Expenses 10199119127138155151156196222195222257
Operating Profit 2617192745583053809494122135
OPM % 20%15%14%18%25%27%17%25%29%30%33%35%34%
Other Income 3111123103-456
Interest 2112554223221
Depreciation 9111010162021232331333540
Profit before tax 187817263582855645590100
Tax % 25%24%23%36%36%28%17%25%26%26%25%25%
Net Profit 13561116257214147416775
EPS in Rs 3.001.141.452.403.725.731.574.819.2910.689.2615.1316.77
Dividend Payout % 33%44%34%0%27%17%0%21%11%9%11%7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-61.54%20.00%83.33%45.45%56.25%-72.00%200.00%95.24%14.63%-12.77%63.41%
Change in YoY Net Profit Growth (%)0.00%81.54%63.33%-37.88%10.80%-128.25%272.00%-104.76%-80.60%-27.40%76.18%

Vimta Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:11%
5 Years:14%
3 Years:8%
TTM:28%
Compounded Profit Growth
10 Years:30%
5 Years:58%
3 Years:17%
TTM:51%
Stock Price CAGR
10 Years:38%
5 Years:72%
3 Years:65%
1 Year:146%
Return on Equity
10 Years:14%
5 Years:17%
3 Years:17%
Last Year:19%

Last Updated: September 5, 2025, 1:51 pm

Balance Sheet

Last Updated: February 1, 2026, 4:08 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 4444444444449
Reserves 116118122132148167169190229276310374407
Borrowings 7426444026323019151997
Other Liabilities 22212342404039495465617995
Total Liabilities 149146176222232237245273306360394467518
Fixed Assets 90888888140135131128162168166230240
CWIP 2065304217012593855
Investments 0000006666000
Other Assets 575882809299105122138174170198224
Total Assets 149146176222232237245273306360394467518

Below is a detailed analysis of the balance sheet data for Vimta Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
  • For Reserves, as of Sep 2025, the value is 407.00 Cr.. The value appears strong and on an upward trend. It has increased from 374.00 Cr. (Mar 2025) to 407.00 Cr., marking an increase of 33.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 95.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 95.00 Cr., marking an increase of 16.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 518.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 230.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 10.00 Cr..
  • For CWIP, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 17.00 Cr..
  • For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 224.00 Cr., marking an increase of 26.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..

Notably, the Reserves (407.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 1715-1243339243759876195
Cash from Investing Activity + -8-8-16-39-24-16-20-32-38-57-76-76
Cash from Financing Activity + -8-91913-8-23-1-5-16-11-2-17
Net Cash Flow 0-12-21131519-172

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow19.0013.00-7.00-17.005.0032.00-2.0023.0061.0079.0075.00113.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 818210010111110011712810293110113
Inventory Days 175158213183209199191140154195260210
Days Payable 8766771841481151141391081248788
Cash Conversion Cycle 169174236100172184194128147164283235
Working Capital Days 6510999226278648987789896
ROCE %16%6%7%11%17%21%6%14%24%24%20%25%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 37.25%37.23%37.00%36.98%36.92%36.89%36.89%36.76%36.70%36.67%35.99%35.89%
FIIs 2.25%2.72%2.74%2.88%5.13%5.16%3.31%3.81%3.66%3.49%4.33%4.59%
DIIs 2.14%2.14%1.50%1.49%1.50%1.49%0.00%1.15%1.43%1.42%0.87%0.11%
Public 58.37%57.92%58.75%58.65%56.45%56.45%59.80%58.28%58.20%58.42%58.80%59.40%
No. of Shareholders 17,16217,43918,42919,95718,55019,05420,11421,15626,18330,82955,93354,467

Shareholding Pattern Chart

No. of Shareholders

Vimta Labs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 330,152 0.1 14.99330,1522025-04-22 17:25:160%
Motilal Oswal S&P BSE Healthcare ETF 78 0.04 0782025-04-22 17:25:160%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 18.5121.7718.709.683.10
Diluted EPS (Rs.) 18.2421.3518.329.683.10
Cash EPS (Rs.) 33.9235.6529.2420.1212.56
Book Value[Excl.RevalReserv]/Share (Rs.) 144.20127.33105.8387.9278.19
Book Value[Incl.RevalReserv]/Share (Rs.) 144.20127.33105.8387.9278.19
Revenue From Operations / Share (Rs.) 143.55143.78125.8695.2981.73
PBDIT / Share (Rs.) 40.9644.4436.9724.3314.91
PBIT / Share (Rs.) 25.5330.5726.4213.895.44
PBT / Share (Rs.) 24.5729.3725.1912.913.74
Net Profit / Share (Rs.) 18.5021.7718.699.683.10
NP After MI And SOA / Share (Rs.) 18.5021.7718.699.683.10
PBDIT Margin (%) 28.5230.9129.3725.5218.24
PBIT Margin (%) 17.7821.2520.9814.576.65
PBT Margin (%) 17.1120.4220.0113.544.57
Net Profit Margin (%) 12.8815.1314.8510.163.78
NP After MI And SOA Margin (%) 12.8815.1314.8510.163.78
Return on Networth / Equity (%) 12.8217.0917.6611.013.95
Return on Capital Employeed (%) 16.3622.1722.5113.926.39
Return On Assets (%) 10.2513.2913.457.802.78
Long Term Debt / Equity (X) 0.020.030.050.070.03
Total Debt / Equity (X) 0.060.050.080.110.13
Asset Turnover Ratio (%) 0.830.950.950.810.00
Current Ratio (X) 2.912.862.602.051.67
Quick Ratio (X) 2.462.462.241.781.37
Dividend Payout Ratio (NP) (%) 10.799.1710.690.0064.60
Dividend Payout Ratio (CP) (%) 5.885.606.830.0015.91
Earning Retention Ratio (%) 89.2190.8389.310.0035.40
Cash Earning Retention Ratio (%) 94.1294.4093.170.0084.09
Interest Coverage Ratio (X) 42.7937.1954.5624.818.76
Interest Coverage Ratio (Post Tax) (X) 20.3319.2129.4110.872.82
Enterprise Value (Cr.) 979.08670.65704.61372.30147.42
EV / Net Operating Revenue (X) 3.082.112.531.770.81
EV / EBITDA (X) 10.786.828.626.924.47
MarketCap / Net Operating Revenue (X) 3.102.192.501.690.72
Retention Ratios (%) 89.2090.8289.300.0035.39
Price / BV (X) 3.082.472.981.830.75
Price / Net Operating Revenue (X) 3.102.192.501.690.72
EarningsYield 0.040.060.050.060.05

After reviewing the key financial ratios for Vimta Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 18.51. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.51, marking a decrease of 3.26.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 18.24. This value is within the healthy range. It has decreased from 21.35 (Mar 23) to 18.24, marking a decrease of 3.11.
  • For Cash EPS (Rs.), as of Mar 24, the value is 33.92. This value is within the healthy range. It has decreased from 35.65 (Mar 23) to 33.92, marking a decrease of 1.73.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.55. It has decreased from 143.78 (Mar 23) to 143.55, marking a decrease of 0.23.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 40.96. This value is within the healthy range. It has decreased from 44.44 (Mar 23) to 40.96, marking a decrease of 3.48.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 30.57 (Mar 23) to 25.53, marking a decrease of 5.04.
  • For PBT / Share (Rs.), as of Mar 24, the value is 24.57. This value is within the healthy range. It has decreased from 29.37 (Mar 23) to 24.57, marking a decrease of 4.80.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
  • For PBDIT Margin (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has decreased from 30.91 (Mar 23) to 28.52, marking a decrease of 2.39.
  • For PBIT Margin (%), as of Mar 24, the value is 17.78. This value is within the healthy range. It has decreased from 21.25 (Mar 23) to 17.78, marking a decrease of 3.47.
  • For PBT Margin (%), as of Mar 24, the value is 17.11. This value is within the healthy range. It has decreased from 20.42 (Mar 23) to 17.11, marking a decrease of 3.31.
  • For Net Profit Margin (%), as of Mar 24, the value is 12.88. This value exceeds the healthy maximum of 10. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.88. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 12.82. This value is below the healthy minimum of 15. It has decreased from 17.09 (Mar 23) to 12.82, marking a decrease of 4.27.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 16.36. This value is within the healthy range. It has decreased from 22.17 (Mar 23) to 16.36, marking a decrease of 5.81.
  • For Return On Assets (%), as of Mar 24, the value is 10.25. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 10.25, marking a decrease of 3.04.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.83. It has decreased from 0.95 (Mar 23) to 0.83, marking a decrease of 0.12.
  • For Current Ratio (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.86 (Mar 23) to 2.91, marking an increase of 0.05.
  • For Quick Ratio (X), as of Mar 24, the value is 2.46. This value exceeds the healthy maximum of 2. There is no change compared to the previous period (Mar 23) which recorded 2.46.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.79. This value is below the healthy minimum of 20. It has increased from 9.17 (Mar 23) to 10.79, marking an increase of 1.62.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.88. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 23) to 5.88, marking an increase of 0.28.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 89.21. This value exceeds the healthy maximum of 70. It has decreased from 90.83 (Mar 23) to 89.21, marking a decrease of 1.62.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.12. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 23) to 94.12, marking a decrease of 0.28.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 37.19 (Mar 23) to 42.79, marking an increase of 5.60.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 19.21 (Mar 23) to 20.33, marking an increase of 1.12.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 979.08. It has increased from 670.65 (Mar 23) to 979.08, marking an increase of 308.43.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.11 (Mar 23) to 3.08, marking an increase of 0.97.
  • For EV / EBITDA (X), as of Mar 24, the value is 10.78. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.78, marking an increase of 3.96.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
  • For Retention Ratios (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 23) to 89.20, marking a decrease of 1.62.
  • For Price / BV (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.08, marking an increase of 0.61.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
  • For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Vimta Labs Ltd as of March 7, 2026 is: ₹374.45

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 7, 2026, Vimta Labs Ltd is Overvalued by 14.70% compared to the current share price ₹439.00

Intrinsic Value of Vimta Labs Ltd as of March 7, 2026 is: ₹421.40

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 7, 2026, Vimta Labs Ltd is Overvalued by 4.01% compared to the current share price ₹439.00

Last 5 Year EPS CAGR: 12.54%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 15.92%, which is a positive sign.
  2. The company has higher reserves (212.15 cr) compared to borrowings (21.38 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (225.92 cr) and profit (39.31 cr) over the years.
  1. The stock has a high average Working Capital Days of 78.92, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 182.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vimta Labs Ltd:
    1. Net Profit Margin: 12.88%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 16.36% (Industry Average ROCE: 17.2%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 12.82% (Industry Average ROE: 13.02%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 20.33
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.46
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 25.8 (Industry average Stock P/E: 32.55)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.06
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Vimta Labs Ltd. is a Public Limited Listed company incorporated on 16/11/1990 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24110TG1990PLC011977 and registration number is 011977. Currently company belongs to the Industry of Medical Research Services. Company's Total Operating Revenue is Rs. 343.98 Cr. and Equity Capital is Rs. 4.45 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Medical Research ServicesPlot Nos. 141/2 & 142, Hyderabad Telangana 500051Contact not found
Management
NamePosition Held
Dr. Sivalinga Prasad VasireddiExecutive Chairman
Ms. Harita VasireddiManaging Director
Mr. Harriman VungalExecutive Director - Operations
Mr. Satya Sreenivas NeerukondaExecutive Director
Dr. Yadagiri R PendriIndependent Director
Ms. Prameela Rani YalamanchiliIndependent Director
Mr. Sanjay DaveIndependent Director
Mr. Purnachandra Rao GuttaIndependent Director

FAQ

What is the intrinsic value of Vimta Labs Ltd?

Vimta Labs Ltd's intrinsic value (as of 07 March 2026) is ₹421.40 which is 4.01% lower the current market price of ₹439.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,959 Cr. market cap, FY2025-2026 high/low of ₹903/372, reserves of ₹407 Cr, and liabilities of ₹518 Cr.

What is the Market Cap of Vimta Labs Ltd?

The Market Cap of Vimta Labs Ltd is 1,959 Cr..

What is the current Stock Price of Vimta Labs Ltd as on 07 March 2026?

The current stock price of Vimta Labs Ltd as on 07 March 2026 is ₹439.

What is the High / Low of Vimta Labs Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Vimta Labs Ltd stocks is ₹903/372.

What is the Stock P/E of Vimta Labs Ltd?

The Stock P/E of Vimta Labs Ltd is 25.8.

What is the Book Value of Vimta Labs Ltd?

The Book Value of Vimta Labs Ltd is 93.3.

What is the Dividend Yield of Vimta Labs Ltd?

The Dividend Yield of Vimta Labs Ltd is 0.23 %.

What is the ROCE of Vimta Labs Ltd?

The ROCE of Vimta Labs Ltd is 25.2 %.

What is the ROE of Vimta Labs Ltd?

The ROE of Vimta Labs Ltd is 19.4 %.

What is the Face Value of Vimta Labs Ltd?

The Face Value of Vimta Labs Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vimta Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports